ag 1879 has been researched along with Cancer of Ovary in 6 studies
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States." | 1.32 | Inhibitors that target protein kinases for the treatment of ovarian carcinoma. ( Arbel, R; Ben-Bassat, H; Hartzstark, Z; Klein, BY; Laufer, N; Levitzki, R; Rojansky, N, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 1 |
| Ahmad, I | 1 |
| Chhikara, BS | 1 |
| Tiwari, R | 1 |
| Mandal, D | 1 |
| Parang, K | 1 |
| Huang, RY | 1 |
| Wang, SM | 1 |
| Hsieh, CY | 1 |
| Wu, JC | 1 |
| Jeong, KJ | 1 |
| Park, SY | 1 |
| Seo, JH | 1 |
| Lee, KB | 1 |
| Choi, WS | 1 |
| Han, JW | 1 |
| Kang, JK | 1 |
| Park, CG | 1 |
| Kim, YK | 1 |
| Lee, HY | 1 |
| Arbel, R | 1 |
| Rojansky, N | 1 |
| Klein, BY | 1 |
| Levitzki, R | 1 |
| Hartzstark, Z | 1 |
| Laufer, N | 1 |
| Ben-Bassat, H | 1 |
| Wakahara, K | 1 |
| Kobayashi, H | 1 |
| Yagyu, T | 1 |
| Matsuzaki, H | 1 |
| Kondo, T | 1 |
| Kurita, N | 1 |
| Sekino, H | 1 |
| Inagaki, K | 1 |
| Suzuki, M | 1 |
| Kanayama, N | 1 |
| Terao, T | 1 |
| Chen, T | 1 |
| Pengetnze, Y | 1 |
| Taylor, CC | 1 |
6 other studies available for ag 1879 and Cancer of Ovary
| Article | Year |
|---|---|
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fe | 2011 |
Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin.
Topics: Adherens Junctions; alpha Catenin; Catenins; Cell Adhesion Molecules; Cell Line, Tumor; Delta Cateni | 2008 |
Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
Topics: Butadienes; Cell Line, Tumor; Cell Movement; CSK Tyrosine-Protein Kinase; Cyclooxygenase 2; ErbB Rec | 2008 |
Inhibitors that target protein kinases for the treatment of ovarian carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Catechols; Cell Cycle; Cell Division; Dose-Response Rel | 2003 |
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Topics: DNA-Binding Proteins; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; MAP | 2004 |
Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.
Topics: Animals; Antineoplastic Agents, Phytogenic; Caspase 3; Caspase 9; Caspases; Cisplatin; Cytochromes c | 2005 |